AR071745A1 - Compuestos sacaridos unidos a heterociclos, inhibidores de polimerasas virales, composiciones farmaceuticas que los comprenden y usos de los mismos como agentes antivirales y/o anticancer. - Google Patents
Compuestos sacaridos unidos a heterociclos, inhibidores de polimerasas virales, composiciones farmaceuticas que los comprenden y usos de los mismos como agentes antivirales y/o anticancer.Info
- Publication number
- AR071745A1 AR071745A1 ARP090100788A ARP090100788A AR071745A1 AR 071745 A1 AR071745 A1 AR 071745A1 AR P090100788 A ARP090100788 A AR P090100788A AR P090100788 A ARP090100788 A AR P090100788A AR 071745 A1 AR071745 A1 AR 071745A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- alkyl
- acyl
- alkynyl
- alkenyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 230000000840 anti-viral effect Effects 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 230000003612 virological effect Effects 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 7
- -1 SO2-alkyl Chemical group 0.000 abstract 6
- 125000002252 acyl group Chemical group 0.000 abstract 6
- 125000003342 alkenyl group Chemical group 0.000 abstract 3
- 125000000304 alkynyl group Chemical group 0.000 abstract 3
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 3
- 229910052757 nitrogen Inorganic materials 0.000 abstract 3
- 125000005017 substituted alkenyl group Chemical group 0.000 abstract 3
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 3
- 125000004426 substituted alkynyl group Chemical group 0.000 abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 abstract 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 2
- 125000005505 thiomorpholino group Chemical group 0.000 abstract 2
- 125000001054 5 membered carbocyclic group Chemical group 0.000 abstract 1
- 125000004008 6 membered carbocyclic group Chemical group 0.000 abstract 1
- 125000001960 7 membered carbocyclic group Chemical group 0.000 abstract 1
- 125000003627 8 membered carbocyclic group Chemical group 0.000 abstract 1
- 229910003827 NRaRb Inorganic materials 0.000 abstract 1
- 239000002777 nucleoside Substances 0.000 abstract 1
- 150000003833 nucleoside derivatives Chemical class 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
- 125000000464 thioxo group Chemical group S=* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/99—Enzyme inactivation by chemical treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02T—CLIMATE CHANGE MITIGATION TECHNOLOGIES RELATED TO TRANSPORTATION
- Y02T10/00—Road transport of goods or passengers
- Y02T10/10—Internal combustion engine [ICE] based vehicles
- Y02T10/30—Use of alternative fuels, e.g. biofuels
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Reivindicacion 1: Un compuesto de formula (1) caracterizado porque B representa un anillo carboc¡clico o heteroc¡clico de 5, 6, 7 u 8 miembros que comprende uno o varios enlaces dobles, en donde B est opcionalmente sustituido con uno o varios oxo, tioxo, NRcRd, F, CI, Br, I, ORz, SRz, alquilo, C:::N, C:::C-R, N3 o SO2R'; en donde: R es H, alquilo o arilo; R' es OH, NH2 o alquilo; R1 es H, NRaRb, CI, F, ORa, SRa, NHCORa, NHSO2Ra, NHCONHRa, CN, alquilo, arilo, ONRaRb o NRaC(O)ORb; R2 es un grupo de azucar nucleosido; Ra y Rb se seleccionan independientemente del grupo que consiste en H, alquilo, alquilo sustituido, alquenilo, alquenilo sustituido, alquinilo, alquinilo sustituido, cicloalquilo, heteroc¡clico, arilo, arilo sustituido, acilo, acilo sustituido, SO2-alquilo, amino, amino sustituido y NO; o Ra y Rb, junto con el nitrogeno al cual est n unidos, forman un anillo pirrolidino, piperidino, piperazino, azetidino, morfolino o tiomorfolino; Rc y Rd se seleccionan independientemente del grupo que consiste en H, alquilo, alquilo sustituido, alquenilo, alquenilo sustituido, alquinilo, alquinilo sustituido, cicloalquilo, acilo, acilo sustituido y SO2-alquilo; o Rc y Rd, junto con el nitrogeno al cual est n unidos, forman un anillo pirrolidino, piperidino, piperazino, azetidino, morfolino o tiomorfolino; y cada Rz se selecciona independientemente del grupo que consiste en H, alquilo, alquilo sustituido, alquenilo, alquenilo sustituido, alquinilo, alquinilo sustituido, cicloalquilo, acilo y acilo sustituido; o una sal o prodroga farmaceuticamente aceptable de dicho compuesto.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3405308P | 2008-03-05 | 2008-03-05 | |
| US7937008P | 2008-07-09 | 2008-07-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR071745A1 true AR071745A1 (es) | 2010-07-14 |
Family
ID=41054287
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090100788A AR071745A1 (es) | 2008-03-05 | 2009-03-05 | Compuestos sacaridos unidos a heterociclos, inhibidores de polimerasas virales, composiciones farmaceuticas que los comprenden y usos de los mismos como agentes antivirales y/o anticancer. |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US7994139B2 (es) |
| EP (1) | EP2265275A2 (es) |
| JP (1) | JP2011525171A (es) |
| KR (1) | KR20100137494A (es) |
| CN (1) | CN102834513A (es) |
| AR (1) | AR071745A1 (es) |
| AU (1) | AU2009221770A1 (es) |
| BR (1) | BRPI0910388A2 (es) |
| CA (1) | CA2717173A1 (es) |
| EA (1) | EA201070988A1 (es) |
| IL (1) | IL207826A0 (es) |
| MX (1) | MX2010009646A (es) |
| NZ (1) | NZ588179A (es) |
| PE (1) | PE20091727A1 (es) |
| TW (1) | TW200942243A (es) |
| WO (1) | WO2009111653A2 (es) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2114980E (pt) * | 2007-01-12 | 2012-09-25 | Biocryst Pharm Inc | Análogos de nucleósidos anti-virais |
| ES2393038T3 (es) | 2007-05-10 | 2012-12-18 | Biocryst Pharmaceuticals, Inc. | Compuestos de tretrahidrofuro[3,4-D]dioxolano para su utlilización en el tratamiento de las infecciones víricas y del cáncer |
| US20090247750A1 (en) * | 2008-03-28 | 2009-10-01 | Biocryst Pharmaceuticals, Inc. | Process for preparing nucleoside analogs |
| WO2009132135A1 (en) | 2008-04-23 | 2009-10-29 | Gilead Sciences, Inc. | 1' -substituted carba-nucleoside analogs for antiviral treatment |
| EP2313102A2 (en) | 2008-07-03 | 2011-04-27 | Biota Scientific Management | Bycyclic nucleosides and nucleotides as therapeutic agents |
| CN102596979B (zh) | 2009-09-21 | 2014-12-10 | 吉里德科学公司 | 用于制备1’-取代碳核苷类似物的方法和中间体 |
| TW201201815A (en) | 2010-05-28 | 2012-01-16 | Gilead Sciences Inc | 1'-substituted-carba-nucleoside prodrugs for antiviral treatment |
| WO2012012465A1 (en) | 2010-07-19 | 2012-01-26 | Clarke, Michael, O'neil Hanrahan | Methods for the preparation of diasteromerically pure phosphoramidate prodrugs |
| BR112013001553B1 (pt) | 2010-07-22 | 2021-01-12 | Gilead Sciences, Inc. | compostos antivirais para o tratamento de infecções por paramyxoviridae e composições farmacêuticas que os compreendem |
| MX348759B (es) | 2010-10-15 | 2017-06-28 | Biocryst Pharm Inc | Metodos y composiciones para inhibicion de polimerasa. |
| WO2013033093A1 (en) * | 2011-08-29 | 2013-03-07 | Biocryst Pharmaceuticals, Inc. | Heterocyclic compounds as janus kinase inhibitors |
| AR090699A1 (es) | 2012-04-18 | 2014-12-03 | Biocryst Pharm Inc | Compuestos inhibidores de la actividad de la arn polimerasa viral |
| US8906929B2 (en) * | 2012-08-16 | 2014-12-09 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
| CN105008369B (zh) * | 2013-03-14 | 2017-07-11 | 百时美施贵宝公司 | 人类免疫缺陷病毒复制抑制剂 |
| CN104946646B (zh) * | 2014-03-25 | 2020-03-31 | 中国医学科学院基础医学研究所 | 用于预防和/或治疗埃博拉病毒性出血热的小核酸分子、dna分子、蛋白及应用 |
| TWI698444B (zh) | 2014-10-29 | 2020-07-11 | 美商基利科學股份有限公司 | 製備核糖苷的方法 |
| DK3265102T3 (da) | 2015-03-06 | 2025-10-13 | Atea Pharmaceuticals Inc | Beta-d-2'-deoxy-2'alpha-fluoro-2'-beta-c-substituerede-2-modificerede-n6-substituerede purinnukleotider til hcv-behandling |
| ES2918585T3 (es) | 2015-09-16 | 2022-07-19 | Gilead Sciences Inc | Métodos para el tratamiento de infecciones por el virus Arenaviridae |
| EP3222292A1 (en) | 2016-03-03 | 2017-09-27 | Heidelberg Pharma GmbH | Amanitin conjugates |
| MX381542B (es) | 2016-03-06 | 2025-03-04 | Biocryst Pharm Inc | Métodos y composiciones para el tratamiento de la infección por el virus del zika. |
| WO2018013937A1 (en) | 2016-07-14 | 2018-01-18 | Atea Pharmaceuticals, Inc. | Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection |
| BR112019004297A2 (pt) | 2016-09-07 | 2019-05-28 | Atea Pharmaceuticals Inc | método, uso de uma quantidade eficaz de um composto, composto, e, composição farmacêutica. |
| HRP20250266T1 (hr) | 2017-02-01 | 2025-04-25 | Atea Pharmaceuticals, Inc. | Nukleotid hemi-sulfat sol za liječenje virusa hepatitisa c |
| CN110869028B (zh) | 2017-03-14 | 2023-01-20 | 吉利德科学公司 | 治疗猫冠状病毒感染的方法 |
| AU2018262501B2 (en) | 2017-05-01 | 2020-12-10 | Gilead Sciences, Inc. | Crystalline forms of (S) 2 ethylbutyl 2 (((S) (((2R,3S,4R,5R) 5 (4 aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2 yl)methoxy)(phenoxy) phosphoryl)amino)propanoate |
| CA3077489A1 (en) | 2017-07-11 | 2019-01-17 | Gilead Sciences, Inc. | Compositions comprising an rna polymerase inhibitor and cyclodextrin for treating viral infections |
| EP3773753A4 (en) | 2018-04-10 | 2021-12-22 | ATEA Pharmaceuticals, Inc. | TREATMENT OF PATIENTS INFECTED WITH THE HEPATITIS C VIRUS WITH CIRRHOSIS |
| WO2020151682A1 (zh) * | 2019-01-23 | 2020-07-30 | 成都先导药物开发股份有限公司 | 一种大环类免疫调节剂 |
| JP2023512656A (ja) | 2020-01-27 | 2023-03-28 | ギリアード サイエンシーズ， インコーポレイテッド | ＳＡＲＳ ＣｏＶ－２感染を治療するための方法 |
| TWI775313B (zh) | 2020-02-18 | 2022-08-21 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| CN118598916A (zh) | 2020-02-18 | 2024-09-06 | 吉利德科学公司 | 抗病毒化合物 |
| TWI883391B (zh) | 2020-02-18 | 2025-05-11 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| US10874687B1 (en) | 2020-02-27 | 2020-12-29 | Atea Pharmaceuticals, Inc. | Highly active compounds against COVID-19 |
| AU2021234308C1 (en) | 2020-03-12 | 2024-02-22 | Gilead Sciences, Inc. | Methods of preparing 1'-cyano nucleosides |
| JP7482250B2 (ja) | 2020-04-06 | 2024-05-13 | ギリアード サイエンシーズ， インコーポレイテッド | １’－シアノ置換カルバヌクレオシド類似体の吸入製剤 |
| PL4157272T3 (pl) | 2020-05-29 | 2025-10-20 | Gilead Sciences, Inc. | Remdesiwir do leczenia zakażeń wirusowych |
| TWI819321B (zh) | 2020-06-24 | 2023-10-21 | 美商基利科學股份有限公司 | 1'-氰基核苷類似物及其用途 |
| WO2022047065A2 (en) | 2020-08-27 | 2022-03-03 | Gilead Sciences, Inc. | Compounds and methods for treatment of viral infections |
| CN117120444A (zh) | 2021-04-16 | 2023-11-24 | 吉利德科学公司 | 使用酰胺制备卡巴核苷的方法 |
| EP4355319A4 (en) | 2021-06-17 | 2025-01-22 | ATEA Pharmaceuticals, Inc. | BENEFICIAL ANTI-HCV COMBINATION THERAPY |
| JP7719954B2 (ja) | 2021-08-18 | 2025-08-06 | ギリアード サイエンシーズ， インコーポレイテッド | リン脂質化合物並びにその製造方法及び使用方法 |
| TWI867455B (zh) | 2022-03-02 | 2024-12-21 | 美商基利科學股份有限公司 | 用於治療病毒感染的化合物及方法 |
| US12357577B1 (en) | 2024-02-02 | 2025-07-15 | Gilead Sciences, Inc. | Pharmaceutical formulations and uses thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ512736A (en) | 1999-01-13 | 2003-11-28 | Genentech Inc | Serine protease inhibitors |
| JP2002279640A (ja) | 2001-03-21 | 2002-09-27 | Ricoh Co Ltd | ウォブル検出回路とその装置 |
| US7429565B2 (en) | 2003-04-25 | 2008-09-30 | Gilead Sciences, Inc. | Antiviral phosphonate analogs |
| AU2004269026B2 (en) | 2003-08-27 | 2010-02-25 | Biota Scientific Management Pty Ltd | Novel tricyclic nucleosides or nucleotides as therapeutic agents |
| US20050182252A1 (en) | 2004-02-13 | 2005-08-18 | Reddy K. R. | Novel 2'-C-methyl nucleoside derivatives |
| WO2006050161A2 (en) | 2004-10-29 | 2006-05-11 | Biocryst Pharmaceuticals, Inc. | Therapeutic furopyrimidines and thienopyrimidines |
| CN101142226A (zh) | 2005-02-28 | 2008-03-12 | 健亚生物科技公司 | 用于治疗病毒感染的三环核苷化合物 |
| US7842672B2 (en) * | 2006-07-07 | 2010-11-30 | Gilead Sciences, Inc. | Phosphonate inhibitors of HCV |
| PT2114980E (pt) | 2007-01-12 | 2012-09-25 | Biocryst Pharm Inc | Análogos de nucleósidos anti-virais |
| ES2393038T3 (es) | 2007-05-10 | 2012-12-18 | Biocryst Pharmaceuticals, Inc. | Compuestos de tretrahidrofuro[3,4-D]dioxolano para su utlilización en el tratamiento de las infecciones víricas y del cáncer |
-
2009
- 2009-03-04 TW TW098107018A patent/TW200942243A/zh unknown
- 2009-03-05 KR KR1020107022136A patent/KR20100137494A/ko not_active Withdrawn
- 2009-03-05 US US12/398,866 patent/US7994139B2/en not_active Expired - Fee Related
- 2009-03-05 AR ARP090100788A patent/AR071745A1/es not_active Application Discontinuation
- 2009-03-05 PE PE2009000334A patent/PE20091727A1/es not_active Application Discontinuation
- 2009-03-05 AU AU2009221770A patent/AU2009221770A1/en not_active Abandoned
- 2009-03-05 CA CA2717173A patent/CA2717173A1/en not_active Abandoned
- 2009-03-05 NZ NZ588179A patent/NZ588179A/xx not_active IP Right Cessation
- 2009-03-05 WO PCT/US2009/036213 patent/WO2009111653A2/en not_active Ceased
- 2009-03-05 BR BRPI0910388A patent/BRPI0910388A2/pt not_active IP Right Cessation
- 2009-03-05 CN CN2009801168793A patent/CN102834513A/zh active Pending
- 2009-03-05 JP JP2010549889A patent/JP2011525171A/ja not_active Withdrawn
- 2009-03-05 EA EA201070988A patent/EA201070988A1/ru unknown
- 2009-03-05 EP EP09716971A patent/EP2265275A2/en not_active Withdrawn
- 2009-03-05 MX MX2010009646A patent/MX2010009646A/es not_active Application Discontinuation
-
2010
- 2010-08-26 IL IL207826A patent/IL207826A0/en unknown
-
2011
- 2011-07-12 US US13/181,078 patent/US20120142617A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009111653A3 (en) | 2011-09-22 |
| CA2717173A1 (en) | 2009-09-11 |
| EA201070988A1 (ru) | 2011-12-30 |
| US20120142617A1 (en) | 2012-06-07 |
| JP2011525171A (ja) | 2011-09-15 |
| AU2009221770A1 (en) | 2009-09-11 |
| PE20091727A1 (es) | 2009-12-04 |
| US20090227524A1 (en) | 2009-09-10 |
| CN102834513A (zh) | 2012-12-19 |
| WO2009111653A2 (en) | 2009-09-11 |
| BRPI0910388A2 (pt) | 2019-06-11 |
| IL207826A0 (en) | 2010-12-30 |
| MX2010009646A (es) | 2010-09-28 |
| NZ588179A (en) | 2012-09-28 |
| US7994139B2 (en) | 2011-08-09 |
| EP2265275A2 (en) | 2010-12-29 |
| KR20100137494A (ko) | 2010-12-30 |
| TW200942243A (en) | 2009-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR071745A1 (es) | Compuestos sacaridos unidos a heterociclos, inhibidores de polimerasas virales, composiciones farmaceuticas que los comprenden y usos de los mismos como agentes antivirales y/o anticancer. | |
| CO7160119A2 (es) | Derivados de imidazo[1,2-b]piridazina como inhibidor de cinasa | |
| AR080074A1 (es) | Naftiridinas sustituidas y su uso como medicamentos | |
| CO2018003565A2 (es) | Compuestos de espiro[3h-indol-3,2´-pirrolidin]-2(1h)-ona y derivados como inhibidores de mdm2-p53 | |
| CO2017012067A2 (es) | Derivado de pirido[3,4–d]pirimidina y sal farmacéuticamente aceptable de éste | |
| AR088441A1 (es) | Compuestos de carboniloximetilfosforamidato sustituido y composiciones farmaceuticas para el tratamiento de infecciones virales | |
| AR077695A1 (es) | Derivados de pirimidina como inhibidores del factor ixa | |
| AR072013A1 (es) | Sulfonamidas n-heterociclicas aneladas con grupo de cabeza de oxadiazolona, procesos para su preparacion y su uso como sustancias farmaceuticas | |
| SV2016005328A (es) | Nuevos derivados de pirazolo pirimidina y su uso como inhibidores de malt1 | |
| MX2016012984A (es) | Derivados indol para uso en medicina. | |
| ES2594409T3 (es) | Derivados de heteroarilo como moduladores del nAChR á7 | |
| AR066583A1 (es) | Derivados de 3,3-espiroindolinona | |
| AR080057A1 (es) | Piridinas disustituidas como anticancerigenos | |
| AR068045A1 (es) | Derivados de catecolamina y prodrogas de los mismos | |
| JP2016530314A5 (es) | ||
| AR073701A1 (es) | Derivados de indol y de indolicina, metodos para su preparacion, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades neurodegenerativas. | |
| ES2684517T3 (es) | Compuestos de heterociclilo como inhibidores de MEK | |
| AR090699A1 (es) | Compuestos inhibidores de la actividad de la arn polimerasa viral | |
| MX347860B (es) | Lípidos y composiciones novedosos para el suministro de agentes terapéuticos. | |
| CL2015002520A1 (es) | Compuestos novedosos de pirimidina y piridina y su uso. | |
| AR086318A1 (es) | Piridil aminopiridinas como inhibidores de syk | |
| AR100006A1 (es) | Derivados de tubulisina | |
| AR048974A1 (es) | Derivados sustituidos del dioxido de oxazol-benzoisotiazol y composiciones farmaceuticas. | |
| CL2019001419A1 (es) | Derivado de pirido[3,4–d]pirimidina y su sal farmacéuticamente aceptable. | |
| HRP20190814T1 (hr) | 7-benzil-4-(2-metilbenzil)-2,4,6,7,8,9-heksahidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(1h)-on, njegove soli i postupci uporabe |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |